{"filing":{"accession_number":"0001193125-26-290768","cik":"0001369568","ticker":"CPRX","company_name":"CATALYST PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"d158010d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1369568/000119312526290768/d158010d8k.htm"},"events":[{"id":15069,"run_id":13441,"accession_number":"0001193125-26-290768","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces topline results from a Phase 1 clinical study of vamorolone (AGAMREE), demonstrating on-target glucocorticoid activity without significant immunosuppression at clinical doses. This is a material clinical milestone for a drug candidate that could support expansion into additional chronic inflammatory rare disease indications. While not a traditional earnings release (which reports financial results), this represents a significant operational/clinical development event that would affect investor assessment of the company's pipeline and commercial prospects.","company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12698,"accession_number":"0001193125-26-290768","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces topline results from a Phase 1 clinical study of vamorolone (AGAMREE), demonstrating on-target glucocorticoid activity without significant immunosuppression at clinical doses. This is a material clinical milestone for a drug candidate that could support expansion into additional chronic inflammatory rare disease indications. While not a traditional earnings release (which reports financial results), this represents a significant operational/clinical development event that would affect investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:23:35.544772+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12698,"accession_number":"0001193125-26-290768","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces topline results from a Phase 1 clinical study of vamorolone (AGAMREE), demonstrating on-target glucocorticoid activity without significant immunosuppression at clinical doses. This is a material clinical milestone for a drug candidate that could support expansion into additional chronic inflammatory rare disease indications. While not a traditional earnings release (which reports financial results), this represents a significant operational/clinical development event that would affect investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:23:35.544772+00:00","company_name":"CATALYST PHARMACEUTICALS, INC.","ticker":"CPRX","filing_date":"2026-06-30"}]}